Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Manjit Tanday"'
Autor:
Neil M. Steven, Alan B. Rickinson, Anthony T. C. Chan, Edwin P. Hui, Steve Wilson, Andrew Hartley, Lesley McGuigan, Ceri Edwards, Claudia Roberts, Jen Matthews, Manjit Tanday, David A. Price, Kristin Ladell, James Turner, Lip Wai Lee, Kevin Harrington, Hui Jia, Graham S. Taylor
Additional detail of materials and methods used. Figure 1. Flow chart detailing dose escalation schema. Figure 2. MVA-EBNA1/LMP2 Vaccination does not alter broad subsets of immune cells. Figure 3. EBNA1 antibody response before and after MVA-EL vacci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac23961963214984f8aa7aeec4fdeb5e
https://doi.org/10.1158/1078-0432.22459926.v1
https://doi.org/10.1158/1078-0432.22459926.v1
Autor:
Neil M. Steven, Alan B. Rickinson, Anthony T. C. Chan, Edwin P. Hui, Steve Wilson, Andrew Hartley, Lesley McGuigan, Ceri Edwards, Claudia Roberts, Jen Matthews, Manjit Tanday, David A. Price, Kristin Ladell, James Turner, Lip Wai Lee, Kevin Harrington, Hui Jia, Graham S. Taylor
Purpose: Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::303abaf52c2dfc85fef0a8480919683b
https://doi.org/10.1158/1078-0432.c.6524349
https://doi.org/10.1158/1078-0432.c.6524349
Autor:
Hui Jia, Anthony T.C. Chan, David Price, Kevin J. Harrington, Lip Wai Lee, Graham S. Taylor, James E. Turner, Alan B. Rickinson, Lesley McGuigan, Edwin P. Hui, Jen Matthews, Neil Steven, Kristin Ladell, Andrew Hartley, Manjit Tanday, Ceri Edwards, Steve Wilson, Claudia Roberts
Publikováno v:
Taylor, G S, Jia, H, Harrington, K, Lee, L W, Turner, J E, Ladell, K, Price, D A, Tanday, M, Matthews, J, Roberts, C, Edwards, C, McGuigan, L, Hartley, A, Wilson, S, Hui, E P, Chan, A T C, Rickinson, A B & Steven, N M 2014, ' A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus (EBV) target antigens : a phase I trial in UK patients with EBV-positive cancer ', Clinical Cancer Research, vol. 20, no. 19, pp. 5009-5022 . https://doi.org/10.1158/1078-0432.CCR-14-1122-T
Purpose: Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor